The potato cyst nematode (PCN), Globodera pallida, attacks potato crops all over the world and is particularly devastating in developing countries where the potato is a subsistence crop. A £1.7 million project led by the University of Leeds to fully sequence its DNA, hopes to shed light on the mechanisms that make the tiny worm such a successful parasite - and lead to methods to sustainably manage this pest.
The research, funded by the Biotechnology and Biological Sciences Research Council (BBSRC), draws together experts from the University of Leeds, the Wellcome Trust Sanger Institute, Rothamsted Research and SCRI, Scotland's leading centre for crop research.
"Although there is partial resistance in some potato varieties, it is very difficult to breed this resistance into commercial ones - so we're tackling the problem from a different perspective," says Dr Peter Urwin from Leeds' Faculty of Biological Sciences. "If we can find out exactly how this worm works so efficiently, it should lead to measures that will help the potato plant to withstand attack."
The worm invades the roots of the potato plant and injects a substance causing the plant to create a unique cell from which it feeds via a specialised tube. By doing this, the nematode stunts root growth and deprives the potato plant of essential nutrients, which leads to lower quality, smaller crops.
Says Dr Urwin: "This tiny parasite has evolved many clever mechanisms that we hope to be able to understand more fully through this research. We have no idea what this injected substance is or how it manages to persuade the plant to create the feeding cell. In addition, its eggs can remain viable in the soil for up to twenty years, with hatching triggered by sensing chemicals released by potato roots nearby. Because of this, once a field is infected, it's almost impossible to get rid of them."
G. pallida is an international problem, affecting the world's two major potato growing regions - the Ukraine and Idaho, USA - as well as 18 countries in the EU and 55 countries world wide. The widespread cultivation of potato varieties such as Maris Piper, which whilst naturally resistant to other PCNs, are not resistant to G. pallida, suggests that the significance of the worm is likely to increase.
UK farmers spend in excess of £50 million a year in efforts to manage the pest. Infestations are currently treated with toxic chemicals, which do not enter the food chain, but are expensive to apply and can make soil sterile, killing other living organisms within it.
Dr Urwin says that controlling G. pallida is essential to maintain the competitiveness of UK potato industry, which together with processing and retail markets is worth some £3 billion per year. "We think that consumers are more likely to support UK production that avoids pesticide residues and environmental harm and that is soundly based on a sustainable approach," he says.
The team hope to complete the sequencing by 2012.
Photo shows female G. pallida feeding on the roots of a potato plant
Graham Askew, Simon Walker, BBSRC (Jan 2018), £699,781
Jennifer Tomlinson, Royal Society (Jan 2018), £512,801
Alex O'Neill and colleagues in Chemistry, BBSRC (Nov 2017), £431,865
Tom Bennett, BBSRC (Oct 2017), £523,679
Neil Ranson, Darren Tomlinson, BBSRC (Oct 2017), £494,318
Nikita Gamper, BBSRC (Oct 2017), £490,426
Amanda Bretman and colleagues from UEA, NERC (Oct 2017), £430,886
Juan Fontana, Rosetrees Trust consumables grant (Oct 2017), £22,500
Helen Miller, DSM Nutritional Products AG (Sep 2017), £69,988
Neil Ranson, Juan Fontana, Mark Harris, Michelle Peckham, Ralf Richter, Peter Stockley, Patricija Van Oosten-Hawle and colleagues in Engineering, FMH and MAPS, Wellcome Trust Equipment Call (Sep 2017), £418,000
Jamie Johnston, Physiological Society (Sep 2017), £10,000
Frank Sobott, Adrian Goldman, Mark Harris, Andrew Macdonald, Stephen Muench, Sheena Radford and colleagues in FMH and MAPS, Wellcome Trust Equipment Call (Aug 2017), £415,000
Ralf Richter, David Brockwell, Eric Hewitt, Jessica Kwok, Emanuele Paci and MAPS/FMH, BBSRC (Jun 2017), £600,000
Eric Blair, Adrian Whitehouse, Nicola Stonehouse, Alison Baker, Richard Bayliss, Joan Boyes, Ryan Seipke, Sally Boxall and MAPS/FMH, BBSRC (Jun 2017), £376,000
Stefan Kepinski, Yoselin Benitez-Alfonso, Tom Bennett, Michelle Peckham, BBSRC (Jun 2017), £331,000
Roman Tuma, Lars Jeuken, Paul Millner, Sheena Radford, Peter Stockley and MAPS/FMH, BBSRC (Jun 2017), £222,000
Vas Ponnambalam, Darren Tomlinson, Stephen Wheatcroft, BHF (May 2017), £107,878
Graham Askew in collaboration with Bangor University, BBSRC (Mar 2017), £477,383
Stephen Muench, BBSRC (Mar 2017), £132,945
Nic Stonehouse, MRC (Mar 2017), £906,341
Bill Kunin, Steve Sait, BBSRC (Mar 2017), £602,831
Adrian Goldman, EU (Mar 2017), £546,576
Sheena Radford, Wellcome Trust (Mar 2017), £1,836,482
Tom Bennett, Royal Society (Mar 2017), £15,000
Jamie Johnston, Royal Society (Mar 2017), £15,000
Beatrice Filippi, Royal Society (Mar 2017), £15,000
Ryan Seipke, BBSRC (Feb 2017), £52,116
Mary O'Connell, BBSRC (Feb 2017), £46,986
Hannah Dugdale, NERC (Feb 2017), £504,138
Anastasia Zhuravleva, EPSRC (Jan 2017), £100,792
Richard Bayliss, Cancer Research UK (Jan 2017), £1,600,000
John Barr, EU (Jan 2017), £339,000
Mark Harris, Royal Society (Jan 2017), £250,000
Alison Dunn, NERC (Jan 2017), £105,000
Alex Breeze, Pancreatic Cancer Research Fund (Jan 2017), £180,000
Alison Dunn, NERC (Dec 2016), £18,000
Lisa Collins, BBSRC (Dec 2016), £1,681,835
Brendan Davies, Leverhulme Trust (Dec 2016), £247,555
Alan Benson, Mark Drinkhill, Ed White, British Heart Foundaion (Dec 2016), £217,223
Adrian Goldman, Royal Society (Dec 2016), £82,999
Lisa Roberts, Alex Breeze, Brendan Davies, Timothy Devinney, Oliver Harlen, Joseph Holden, Anthea Hucklesby, Pamela Jones, Philip Mellor, RCUK (Nov 2016), £484,172
Lisa Roberts, Alex Breeze, Brendan Davies, Timothy Devinney, Oliver Harlen, Joseph Holden, Anthea Hucklesby, Pamela Jones, Philip Mellor, Wellcome Trust (Nov 2016), £119,343
Katie Field, Rank Prize Funds (Nov 2016), £20,000
Jessica Kwok, Royal Society (Nov 2016), £14,948
John Ladbury, Cancer Research UK (Oct 2016), £4,250